Edition:
United States

Sun Pharma Advanced Research Company Ltd (SPRC.NS)

SPRC.NS on National Stock Exchange of India

287.20INR
26 May 2017
Change (% chg)

Rs5.50 (+1.95%)
Prev Close
Rs281.70
Open
Rs281.00
Day's High
Rs289.95
Day's Low
Rs279.25
Volume
181,437
Avg. Vol
226,752
52-wk High
Rs414.90
52-wk Low
Rs270.00

Latest Key Developments (Source: Significant Developments)

Sun Pharma Advanced Research June-qtr loss widens
Friday, 29 Jul 2016 05:32am EDT 

Sun Pharma Advanced Research Company Ltd : June-quarter net loss 364.1 million rupees versus loss of 16.5 million rupees last year . June-quarter total income from operations 214.8 million rupees versus 434.4 million rupees last year .  Full Article

Sun Pharma and Almirall signs license deal for Psoriasis treatment
Wednesday, 27 Jul 2016 10:32pm EDT 

Sun Pharmaceutical Industries Ltd : Almirall and Sun Pharma enter into a license agreement for Tildrakizumab in Europe for Psoriasis . To receive development & regulatory milestone payments, royalties, the terms of which are confidential .  Full Article

Almirall signs license deal with Sun Pharma for psoriasis treatment
Wednesday, 27 Jul 2016 11:57am EDT 

Almirall SA : Says enters into a license agreement with Sun Pharma Industries for tildrakizumab in Europe for psoriasis . Says to pay Sun Pharma an initial upfront payment of $50 million . Says Sun Pharma will be eligible to get milestone payments, sales milestone payments and royalties on net sales .Says phase-3 studies of tildrakizumab have recently been completed.  Full Article

Sun Pharma Advanced Research March-qtr net loss widens
Friday, 6 May 2016 06:01am EDT 

Sun Pharma Advanced Research Company Ltd : March quarter net loss 95.8 million rupees versus loss of 94 million rupees . March quarter total income from operations 411.7 million rupees versus 427 million rupees .  Full Article

Sun Pharma Advanced Research Co Ltd Receives Complete Response Letter (CRL) from USFDA for Levetiracetam NDA
Friday, 25 Sep 2015 11:07pm EDT 

Sun Pharma Advanced Research Co Ltd:Announces that the U.S. Food and Drug Administration (USFDA) has issued a Complete Response letter (CRL) to its New Drug Application (NDA) for Elepsia XRTM (Levetiracetam extended-release tablets 1000 mg and 1500 mg).Had earlier received a final approval from USFDA in March 2015 for this product and was evaluating several marketing partners for commercialization.Has now received a CRL from the USFDA rescinding its earlier approval, citing that the compliance status of the manufacturing facility was not acceptable on the date of approval.  Full Article

More From Around the Web

BRIEF-India's Sun Pharma Advanced Research March-qtr loss widens

* Net loss in March quarter last year was 95.8 million rupees as per Ind-As; total revenue was 434.9 million rupees Source text: http://bit.ly/2q6aPWX Further company coverage: